This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Consolidated September 2026 quarter revenue up 26.6%, profit after tax up 60.2% year on year
AARTIDRUGS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.8 pts less than Nifty Microcap 250 and 3.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
On a consolidated basis for the quarter ended September 30, 2026, revenue from operations was Rs 826.24 crore versus Rs 652.79 crore in the year-ago quarter, up 26.6%, while profit after tax was Rs 132.90 crore versus Rs 82.94 crore, up 60.2%. The quarter also included a Rs 37 lakh exceptional charge. Auditors gave an unmodified opinion, and operating margin strengthened by about 9 percentage points.
Strong revenue, profit and margin gains may support positive investor sentiment, although the small exceptional charge is a minor negative.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹826.2 Cr | ₹652.8 Cr | +26.6% |
| Operating profit | ₹106.7 Cr | ₹60.32 Cr | +76.9% |
| Profit after tax | ₹82.77 Cr | ₹45.16 Cr | +83.3% |
| EBITDA margin | 16.4% | 12.9% | +3.5 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.